Indian Preventive Inhaler Market Top Leading Players with Strategies and Forecast 2025

Indian preventive inhaler market is anticipated to grow at a substantial rate of 7.0% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the country. The Indian preventive inhaler market is segmented on the basis of device type, application, and end-user. On the basis of device type, the market is sub-segmented into the metered dosed inhaler and dry powdered inhaler. The dry powder preventive inhaler is estimated to have the largest market share in the Indian preventive inhaler market due to providing an easy inhalation solution. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

To Request a Sample of our Report on Indian Preventive Inhaler Market: https://www.omrglobal.com/request-sample/indian-preventive-inhaler-market

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing preventive inhalers to cater to a wide range of customers within the region and across the globe. The major players of the Indian preventive inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, Propeller Health, Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Cipla is one of the major companies working in the preventive inhaler industry. The company offers products in the field of asthma, COPD, Allergic Rhinitis (AR), Pulmonary Arterial Hypertension (PAH), lung cancer and Idiopathic Pulmonary Fibrosis (IPF). In May 2018, the company established a partnership with MannKind for marketing and distributing Afrezza. It is the only US FDA approved inhaled insulin available for patients suffering from diabetes. In addition, the company in February 2018, has entered into a partnership with Roche Pharma India for healthcare improvement and increasing access to life-changing medicines in India.

(Get 15% Discount on Buying this Report)

A full Report of Indian Preventive Inhaler Market is Available @ https://www.omrglobal.com/industry-reports/indian-preventive-inhaler-market

Indian Preventive Inhaler Market Segmentation

By Device Type

· Metered Dose Inhaler

· Dry Powder Inhaler

By Application

· Asthma

· Chronic Obstructive Pulmonary Disease (COPD)

By End-User

· Homecare

· Hospitals and Clinics

Company Profiles

· 3M Co.

· Acorda Therapeutics, Inc.

· Adamis Pharmaceuticals Corp.

· Adherium Ltd.

· Aradigm Corp.

· AstraZeneca PLC

· Boehringer Ingelheim International GmbH

· Cipla Ltd.

· GlaxoSmithKline PLC

· Koninklijke Philips N.V.

· MidasCare Pharmaceutical Pvt. Ltd.

· Novartis AG

· Omron Healthcare Inc.

· Sunovion Pharmaceuticals

· Teva Pharmaceuticals Industries Ltd.

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.